Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis.
The immunoprotective behaviour of the 30-kDa secretory glycoprotein of Mycobacterium tuberculosis H37Rv has been investigated in different adjuvant systems in two mouse strains, NMR1 and C57BL/6J. In comparison with Freund's incomplete adjuvant (FIA) and dimethyldioctadecyl ammonium bromide (DDA), the 30-kDa glycoprotein complexed with polylactide-co-glycolide microparticles (PLG-MPs) induced maximum immunoreactivity in the two mouse strains. As compared with controls, immunisation with 30-kDa-PLG-MPs resulted in significantly greater protection in animals challenged with 1 x LD50 of M. tuberculosis H37Rv on the basis of survival rates and number of cfu in the infected organs 30 days after challenge. The degree of protection provided by 30-kDa-PLG-MPs was similar to that obtained with 30-kDa-FIA and higher than BCG immunisation. These findings suggest that biodegradable PLG microparticles can be used as an efficient carrier system for the key immunoprotective 30-kDa secretory protein antigen of M. tuberculosis H37Rv.
Sharma
Anil K
AK
Verma
Indu
I
Tewari
R
R
Khuller
G K
GK
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000595:Amino Acid Sequence; D000818:Animals; D001500:BCG Vaccine / Q000494:pharmacology; D001426:Bacterial Proteins / Q000276:immunology / Q000302:isolation & purification / Q000494:pharmacology*; D005260:Female; D007114:Immunization; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D008969:Molecular Sequence Data; D009169:Mycobacterium tuberculosis / Q000276:immunology*; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016896:Treatment Outcome; D014376:Tuberculosis / Q000382:microbiology / Q000517:prevention & control*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D001426:Bacterial Proteins